A recent study evaluated the effects of tofacitinib, a JAK1/JAK3 inhibitor, on inflammation and cardiovascular safety in rheumatoid arthritis models. Researchers performed coculture experiments with activated peripheral blood mononuclear cells and either RA synoviocytes or endothelial cells, finding that while tofacitinib effectively suppressed inflammatory cytokines, it did not alleviate prothrombotic changes in endothelial cells. This raises concerns about cardiovascular risks despite its anti-inflammatory benefits. Insightful conclusions were drawn regarding IL-17A’s resistance to inhibition and the need for combined therapies targeting coagulation pathways.

Source: ACR Open Rheumatology